NASDAQ:ONCO Onconetix Q3 2024 Earnings Report $1.10 -0.03 (-2.21%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Onconetix EPS ResultsActual EPS-$9,520.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOnconetix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnconetix Announcement DetailsQuarterQ3 2024Date12/9/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnconetix's Q2 2026 earnings is estimated for Monday, August 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Onconetix Earnings HeadlinesOnconetix (NASDAQ:ONCO) Trading Down 6.5% - Here's WhyJune 25, 2026 | americanbankingnews.comOnconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School DistrictJune 24, 2026 | markets.businessinsider.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 1 at 1:00 AM | Paradigm Press (Ad)Onconetix Announces Realbotix Optio and M-Series Humanoid Robot Pilot at Salamanca City Central School DistrictJune 24, 2026 | quiverquant.comQOnconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School DistrictJune 24, 2026 | globenewswire.comOnconetix, Inc. Announces 1-for-10 Reverse Stock SplitMay 19, 2026 | globenewswire.comSee More Onconetix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email. Email Address About OnconetixOnconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.View Onconetix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Charts That Could Change the Course of Summer TradingWhy Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofBurger King’s Turnaround Is Putting Restaurant Brands Back in FocusPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After Earnings Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
